Kanghong Pharmaceutical (002773.SZ): Compesip ophthalmic injections are included in the national medical insurance catalogue

Zhitongcaijing · 2d ago

Zhitong Financial App News, Kanghong Pharmaceutical (002773.SZ) issued an announcement. On December 7, 2025, the National Medical Security Administration website published the “Notice of the Ministry of Human Resources and Social Security of the National Health Insurance Administration on Issuing the 'National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” and the 'Commercial Health Insurance Innovative Drug Catalogue (2025) '(Health Insurance Administration (2025) No. 33). Compassic Eye Injection (product name “Langmu”) was included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025) B” Class.

As the only domestically produced innovative drug covering the four major indications of fundus disease in the current catalogue, compassic ophthalmic injections are included in the routine catalogue management, reflecting the National Health Insurance Administration's recognition of the innovative achievements, clinical value, and patient benefits of this variety, and will further enhance the stability and accessibility of medication for patients. At the same time, the company is also actively carrying out phase III clinical trials of high-dose varieties of compassic, as well as clinical trials of gene therapy drugs KH631 and KH658 in China and the US, hoping to benefit more patients through high-quality innovation.